Quality Agreement Drafting

Pharmaceutical Excipient Quality Agreement Formulation & Clause Guide

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Guiding excipient manufacturers to draft and negotiate Quality Agreements per IPEC rules, detailing change notification windows and audit access.

Key answer

An excipient Quality Agreement is a legal document defining QMS responsibilities between drug manufacturers and excipient suppliers. Drafting must align with IPEC guidelines. Key clauses include: defining "major changes" (site moves, equipment swaps, solvent changes) and setting mandatory notification windows (typically 180 days beforehand); detailing OOS and deviation report times; and mapping buyer onsite audit frequencies.

Core Elements of an IPEC-Compliant Quality Agreement

The Quality Agreement must remain independent of commercial purchase orders. Its core mission is setting up the GMP compliance boundaries.

  • Change Control: notification deadlines for changes in synthesis routes, containers, or specifications
  • Non-conformance: mapping coordination duties during batch scrap, recalls, or regulatory audits
  • Records retention: legal duties to retain production logs, chromatograms, and stability tests for 5-7 years

FAQ

What is the recommended change notification window?+

Per IPEC guidelines, major changes require 180 days advance written notice to allow drug firms to run compatibility evaluations or file variations. Moderate changes usually require a 90-day notice.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.